Artículos por temáticas

Potential of triazines in Alzheimer's disease: A versatile privileged scaffold

Gharat R, Prabhu A, Khambete MP.

Arch Pharm (Weinheim). 2022 Apr;355(4):e2100388. doi: 10.1002/ardp.202100388. Epub 2022 Jan 11.

Extra-Virgin Olive Oil Enhances the Blood-Brain Barrier Function in Mild Cognitive Impairment: A Randomized Controlled Trial

Kaddoumi A, Denney TS Jr, Deshpande G, Robinson JL, Beyers RJ, Redden DT, Praticò D, Kyriakides TC, Lu B, Kirby AN, Beck DT, Merner ND.

Nutrients. 2022 Dec 1;14(23):5102. doi: 10.3390/nu14235102.

Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial

Teng E, Manser PT, Pickthorn K, Brunstein F, Blendstrup M, Sanabria Bohorquez S, Wildsmith KR, Toth B, Dolton M, Ramakrishnan V, Bobbala A, Sikkes SAM, Ward M, Fuji RN, Kerchner GA; Tauriel Investigat

JAMA Neurol. 2022 Aug 1;79(8):758-767. doi: 10.1001/jamaneurol.2022.1375.

Supplementation With Carotenoids, Omega-3 Fatty Acids, and Vitamin E Has a Positive Effect on the Symptoms and Progression of Alzheimer's Disease

Nolan JM, Power R, Howard AN, Bergin P, Roche W, Prado-Cabrero A, Pope G, Cooke J, Power T, Mulcahy R.

J Alzheimers Dis. 2022;90(1):233-249. doi: 10.3233/JAD-220556.

Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer's disease

Dhadda S, Kanekiyo M, Li D, Swanson CJ, Irizarry M, Berry S, Kramer LD, Berry DA.

Alzheimers Res Ther. 2022 Dec 9;14(1):182. doi: 10.1186/s13195-022-01129-x.

Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials

Ostrowitzki S, Bittner T, Sink KM, Mackey H, Rabe C, Honig LS, Cassetta E, Woodward M, Boada M, van Dyck CH, Grimmer T, Selkoe DJ, Schneider A, Blondeau K, Hu N, Quartino A, Clayton D, Dolton M, Dang

JAMA Neurol. 2022 Nov 1;79(11):1113-1121. doi: 10.1001/jamaneurol.2022.2909.

Porphyromonas gingivalis, neuroinflammation and Alzheimer's disease

Owoyele PV, Malekzadeh S.

Niger J Physiol Sci. 2022 Dec 31;37(2):157-164. doi: 10.54548/njps.v37i2.1.

Role of HSV-1 in Alzheimer's disease pathogenesis: A challenge for novel preventive/therapeutic strategies

Protto V, Marcocci ME, Miteva MT, Piacentini R, Li Puma DD, Grassi C, Palamara AT, De Chiara G.

Curr Opin Pharmacol. 2022 Apr;63:102200. doi: 10.1016/j.coph.2022.102200. Epub 2022 Mar 8.

Early-stage Alzheimer disease: getting trial-ready

Aisen PS, Jimenez-Maggiora GA, Rafii MS, Walter S, Raman R.

Nat Rev Neurol. 2022 Jul;18(7):389-399. doi: 10.1038/s41582-022-00645-6. Epub 2022 Apr 4.

Alzheimer's disease failed clinical trials

Asher S, Priefer R.

Life Sci. 2022 Oct 1;306:120861. doi: 10.1016/j.lfs.2022.120861. Epub 2022 Aug 4.

Editorial: The dawn of a new era of Alzheimer's research and drug development

Hara Y, Fillit HM.

J Prev Alzheimers Dis. 2022;9(3):385-386. doi: 10.14283/jpad.2022.64.

Optogenetics: implications for Alzheimer's disease research and therapy

Mirzayi P, Shobeiri P, Kalantari A, Perry G, Rezaei N.

Mol Brain. 2022 Feb 23;15(1):20. doi: 10.1186/s13041-022-00905-y.

Hope on the horizon for Alzheimer's disease treatment?

The Lancet Healthy Longevity.

Lancet Healthy Longev. 2022 Nov;3(11):e722. doi: 10.1016/S2666-7568(22)00251-3.

Dementia Prevention in Clinical Practice

Niotis K, Akiyoshi K, Carlton C, Isaacson R.

Semin Neurol. 2022 Oct;42(5):525-548. doi: 10.1055/s-0042-1759580. Epub 2022 Nov 28.

Exploring New Vista for Alzheimer's Disease Drug Targets

Kumar D.

Curr Top Med Chem. 2022;22(22):1847-1848. doi: 10.2174/156802662222221007161622.